Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure-Reference-Cited by-同舟云学术

Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure

Published:2015-06-15 Issue:12 Volume:22 Page:992-1001
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Ogawa E.¹,Furusyo N.¹,Dohmen K.²,Kajiwara E.³,Kawano A.⁴,Nomura H.⁵,Takahashi K.⁶,Satoh T.⁷,Azuma K.⁸,Nakamuta M.⁹,Koyanagi T.¹⁰,Kotoh K.¹¹,Shimoda S.¹²,Hayashi J.¹³,

Affiliation:

1. Department of General Internal Medicine; Kyushu University Hospital; Fukuoka Japan

2. Department of Internal Medicine; Chihaya Hospital; Fukuoka Japan

3. Department of Hepatology; Steel Memorial Yawata Hospital; Kitakyushu Japan

4. Department of Medicine; Kitakyushu Municipal Medical Center; Kitakyushu Japan

5. The Center for Liver Disease; Shin-Kokura Hospital; Kitakyushu Japan

6. Department of Medicine; Hamanomachi Hospital; Fukuoka Japan

7. Center for Liver Disease; National Hospital Organization Kokura Medical Center; Kitakyushu Japan

8. Department of Medicine; Kyushu Central Hospital; Fukuoka Japan

9. Department of Gastroenterology; Kyushu Medical Center; National Hospital Organization; Fukuoka Japan

10. Department of Medicine; Fukuoka City Hospital; Fukuoka Japan

11. Department of Medicine and Bioregulatory Science; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

12. Department of Medicine and Biosystemic Science; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

13. Kyushu General Internal Medicine Center; Haradoi Hospital; Fukuoka Japan

Funder

MSD K.K.

Chugai Pharmaceutical Co.

Mitsubishi Tanabe Pharma Co.

Janssen Pharmaceutical K.K.

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jvh.12427/fullpdf

Reference32 articles.

1. Epidemiology of viral hepatitis and hepatocellular carcinoma;El-Serag;Gastroenterology,2012

2. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence;Mohd Hanafiah;Hepatology,2013

3. Outcome of sustained virological responders with histologically advanced chronic hepatitis C;Morgan;Hepatology,2010

4. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study;Ogawa;J Hepatol,2013

5. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C;Karino;J Viral Hepat,2014

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus;Gut and Liver;2017-07-15

2. Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection;Hepatology Research;2016-10-26

3. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1;Journal of Gastroenterology;2016-05-28

4. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin;International Journal of Medical Sciences;2016

5. Multiple drugs;Reactions Weekly;2015-12